Abstract
Respiratory diseases, both acute or chronic and infectious or non-infectious, affect millions of people worldwide. The leading causes of morbidity and mortality due to respiratory diseases like asthma, chronic obstructive pulmonary diseases, interstitial lung diseases, cystic fibrosis (CF), respiratory infections and lung cancers impose enormous socio-economic burdens. Despite the significant improvement in understanding the mechanisms of these disease processes, only a few effective therapies have been developed, and most of the treatments reduce the symptoms but do not prevent the disease. There is a need for the development of efficacious respiratory drugs as well as the drug delivery system to reduce health care burdens and improve patient outcomes. Pulmonary drug delivery has not been fully explored, considering the increasing complexity of respiratory diseases, which demands an emerging need for suitable, effective and patient-complaint pharmaceuticals. In this chapter, we provide an overview of the burden of respiratory diseases, current treatments and limitations; a brief outline of chronic lung diseases and their pathogenic mechanisms; and the need for the development of novel and effective pulmonary drug delivery systems.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abegunde DO et al (2007) The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 370(9603):1929–1938
Allen DB et al (2003) Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 112(3 Suppl):S1–S40
Amir Sharafkhaneh NAH, Kim V (2008) Pathogenesis of emphysema. Proc Am Thorac Soc 5:475–477
Anderson CF et al (2020) Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases. Wiley interdisciplinary reviews. Nanomed Nanobiotechnol 12(1):e1586–e1586
Antoniou KM et al (2014) Interstitial lung disease. Eur Respir Rev 23(131):40–54
Ashkenazi-Hoffnung L et al (2018) A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study. Eur J Clin Microbiol Infect Dis 37(7):1361–1371
Astma GIF (2020) GINA Report, Global Strategy for Asthma Management and Prevention
Bakshi HA et al (2020) Dietary crocin is protective in pancreatic cancer while reducing radiation-induced hepatic oxidative damage. Nutrients:12(6)
Barnes PJ (2000) Chronic obstructive pulmonary disease. N Engl J Med 343(4):269–280
Barnes PJ (2013) Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 131(3):636–645
Beck-Broichsitter M, Merkel OM, Kissel T (2012) Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J Control Release 161(2):214–224
Bordon J et al (2013) Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis 17(2):e76–e83
Boubour A, Paradkar M, Thakur KT (2020) Chapter 1—Global and regional burden of tuberculosis and tuberculous meningitis. In: Chin JH-C (ed) Tuberculous meningitis. Academic Press, pp 1–15
Brambilla E et al (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18(6):1059–1068
Burgel P-R et al (2011) Update on the roles of distal airways in COPD. Eur Respir Rev 20(119):007–022
Cazzola M et al (2020) Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv 17(5):635–646
Chandel A et al (2019) Recent advances in aerosolised drug delivery. Biomed Pharmacother 112:108601
Chooi YC, Ding C, Magkos F (2019) The epidemiology of obesity. Metabolism 92:6–10
Chow A et al (2007) Particle engineering for pulmonary drug delivery. Pharm Res 24:411–437
Chung KF, Adcock IM (2008) Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 31(6):1334–1356
Cillóniz C, Cardozo C, García-Vidal CJ (2018) Epidemiology, pathophysiology, and microbiology of communityacquired pneumonia. Ann Res Hosp 2(1)
Cottin V et al (2018) Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev:27(150)
Cryan S-A (2005) Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 7(1):E20–E41
Dandachi D, Rodriguez-Barradas MC (2018) Viral pneumonia: etiologies and treatment. J Investig Med 66(6):957–965
Daniels CE et al (2010) Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 181(6):604–610
Davies DE et al (2003) Airway remodeling in asthma: new insights. J Allergy Clin Immunol 111(2):215–225; quiz 226
Davies JC, Alton EW, Bush A (2007) Cystic fibrosis. BMJ 335(7632):1255–1259
de Benedictis FM, Bush A (2012) Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med 185(1):12–23
Demedts M et al (2001) Interstitial lung diseases: an epidemiological overview. Eur Respir J Suppl 32:2s–16s
Desai O et al (2018) The role of immune and inflammatory cells in idiopathic pulmonary fibrosis. Front Med (Lausanne) 5:43
Elborn JS (2016) Cystic fibrosis. Lancet 388(10059):2519–2531
El-Gendy N, Bailey MM, Berkland C (2011) Particle engineering technologies for pulmonary drug delivery. In: Smyth HDC, Hickey AJ (eds) Controlled pulmonary drug delivery. Springer, New York, NY, pp 283–312
El-Sherbiny IM et al (2011) Overcoming lung clearance mechanisms for controlled release drug delivery. In: Smyth HDC, Hickey AJ (eds) Controlled pulmonary drug delivery. Springer, New York, NY, pp 101–126
Fahy JV (2015) Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol 15(1):57–65
Fergeson JE, Patel SS, Lockey RF (2017) Acute asthma, prognosis, and treatment. J Allergy Clin Immunol 139(2):438–447
Flaster H et al (2007) The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 21(6):1267–1280
Gillis RJ, Iglewski BH (2004) Azithromycin retards Pseudomonas aeruginosa biofilm formation. J Clin Microbiol 42(12):5842–5845
Gosselink JV et al (2010) Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181(12):1329–1335
Goyal V, Chang AB (2016) Acute exacerbations of airway inflammation. In: Parnham MJ (ed) Compendium of inflammatory diseases. Springer, Basel, pp 5–20
Guarascio AJ et al (2013) The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res 5:235–245
Gupta P, O’Mahony MS (2008) Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people. Drugs Aging 25(5):415–443
Hamid Q et al (2003) Inflammatory cells in asthma: mechanisms and implications for therapy. J Allergy Clin Immunol 111(1 Suppl):S5–S12; discussion S12–S7
Hogg JC (2004a) Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364(9435):709–721
Hogg JC (2004b) Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364(9435):709–721
Hogg JC, Timens W (2009) The pathology of chronic obstructive pulmonary disease. Ann Rev Pathol Mechan Dis 4(1):435–459
Holgate ST et al (2015) Asthma. Nat Rev Dis Primers 1(1):15025
Huang H, Lovell JF (2017) Advanced functional nanomaterials for theranostics. Adv Funct Mater 27(2):1603524
Hurley MN et al (2014) Rate of improvement of CF life expectancy exceeds that of general population—observational death registration study. J Cyst Fibros 13(4):410–415
Janssens JP, Krause KH (2004) Pneumonia in the very old. Lancet Infect Dis 4(2):112–124
Jilani TN, Jamil RT, Siddiqui AH (2020) H1N1 Influenza (Swine Flu). In: StatPearls. StatPearls Publishing, Treasure Island, FL
Kalchiem-Dekel O et al (2018) Interstitial lung disease and pulmonary fibrosis: a practical approach for general medicine physicians with focus on the medical history. J Clin Med:7(12)
Keatings VM et al (1997) Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155(2):542–548
Khaltaev N (2017) GARD, a new way to battle with chronic respiratory diseases, from disease oriented programmes to global partnership. J Thorac Dis 9(11):4676–4689
Knowles MR et al (1997) Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest 100(10):2588–2595
Kuruvilla ME, Lee FE, Lee GB (2019) Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol 56(2):219–233
Kusano S et al (1995) Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease. Respiration 62(4):217–222
Labaki WW, Han MK (2020) Chronic respiratory diseases: a global view. Lancet Respir Med 8(6):531–533
Lavorini F, Pistolesi M, Usmani OS (2017) Recent advances in capsule-based dry powder inhaler technology. Multidiscip Respir Med 12(1):11
Lederer DJ, Martinez FJ (2018) Idiopathic pulmonary fibrosis. N Engl J Med 378(19):1811–1823
Liu L et al (2015) Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 385(9966):430–440
Lozano R et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095–2128
Lundback B et al (2003) Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 97(2):115–122
MacKenzie T et al (2014) Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med 161(4):233–241
Madan J, et al (2013) Formulation and evaluation of microspheres containing ropinirole hydrochloride using biodegradable polymers
Mapel DW et al (2015) Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity. Int J Chron Obstruct Pulmon Dis 10:1477–1486
Martinez FJ et al (2017) Idiopathic pulmonary fibrosis. Nat Rev Dis Primers 3:17074
Matera MG, Page CP, Cazzola M (2011) Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 32(8):495–506
Matera MG et al (2018) Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert Opin Pharmacother 19(18):2043–2053
Matera MG et al (2020) Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev 72(1):218
McKimm-Breschkin JL (2013) Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 7(Suppl 1):25–36
Menéndez R et al (2012) Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 141(6):1537–1545
Miravitlles M, Anzueto A (2013) Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 188(9):1052–1057
Molfino NA, Jeffery PK (2007) Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies. Pulm Pharmacol Ther 20(5):462–472
Nagai H et al (1991) Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 58(3–4):145–149
Newman SP (2004) Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther 4(1):23–33
Nunes C, Pereira A, Morais-Almeida M (2017) Asthma costs and social impact. Asthma Res Pract 3
Page C, Cazzola M (2017) Bifunctional drugs for the treatment of respiratory diseases. Handb Exp Pharmacol 237:197–212
Page CP, Spina D (2012) Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 12(3):275–286
Papi A et al (2018) Asthma. Lancet 391(10122):783–800
Patil JS, Sarasija S (2012) Pulmonary drug delivery strategies: a concise, systematic review. Lung India 29(1):44–49
Pavord ID et al (2018) After asthma: redefining airways diseases. Lancet 391(10118):350–400
Pettersen CA, Adler KB (2002) Airways inflammation and COPD: epithelial-neutrophil interactions. Chest 121(5 Suppl):142S–150S
Pfuntner A, Wier LM, Steiner C (2006) Costs for Hospital Stays in the United States, 2011: Statistical Brief #168, in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality (US), Rockville, MD
Pneumonia—Our World in Data (2019). https://ourworldindata.org/pneumonia
Prüss-Üstün A, Corvalán CF, World Health Organization (2006) Preventing disease through healthy environments: towards an estimate of the environmental burden of disease. World Health Organization, Geneva
Raghu G et al (2013) Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 158(9):641–649
Ramsey CD, Celedón JC (2005) The hygiene hypothesis and asthma. Curr Opin Pulm Med 11(1):14–20
Rangasamy T et al (2009) Cigarette smoke-induced emphysema in A/J mice is associated with pulmonary oxidative stress, apoptosis of lung cells, and global alterations in gene expression. Am J Physiol Lung Cell Mol Physiol 296(6):L888–L900
Ray A, Oriss TB, Wenzel SE (2015) Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol 308(2):L130–L140
Renna M et al (2011) Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 121(9):3554–3563
Rey MM, Bonk MP, Hadjiliadis D (2019) Cystic fibrosis: emerging understanding and therapies. Annu Rev Med 70:197–210
Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med 353(16):1711–1723
Robinson DS (2010) The role of the T cell in asthma. J Allergy Clin Immunol 126(6):1081–1091. quiz 1092-3
Robinson D et al (2017) Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy 47(2):161–175
Rubin BK (2018) Cystic fibrosis 2017-the year in review. Respir Care 63(2):238–241
Rudan I et al (2013) Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health 3(1):010401
Ryu JH et al (2007) Diagnosis of interstitial lung diseases. Mayo Clin Proc 82(8):976–986
Saetta M, Turato G (2001) Airway pathology in asthma. Eur Respir J Suppl 34:18s–23s
Saettaa GTRZM (2001) Pathogenesis and pathology of COPD. Respiration 68(2):117–128
Salazar LM, Herrera AM (2011) Fibrotic response of tissue remodeling in COPD. Lung 189(2):101–109
Sethi GR, Singhal KK (2008) Pulmonary diseases and corticosteroids. Indian J Pediatr 75(10):1045–1056
Smyth A, Walters S (2001) Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2001(3):Cd001912
Snider GL (1989) Chronic obstructive pulmonary disease: risk factors, pathophysiology and pathogenesis. Annu Rev Med 40:411–429
So JY, Mamary AJ, Shenoy K (2018) Asthma: diagnosis and treatment. Eur Med J 3(4):111–121
Sohrabi C et al (2020) World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 76:71–76
Soriano JB et al (2020) Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med 8(6):585–596
Spahn JD et al (2001) Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 87(6):501–505
Spina D (2014) Current and novel bronchodilators in respiratory disease. Curr Opin Pulm Med 20(1):73–86
Suresh Babu K (2013) J. Kastelik, and J.B. Morjaria, Role of long term antibiotics in chronic respiratory diseases. Respir Med 107(6):800–815
Takizawa H et al (1997) Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 156(1):266–271
Tamaoki J et al (1995) Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 39(8):1688–1690
Tashkin DP et al (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359(15):1543–1554
Taylor JD (2010) COPD and the response of the lung to tobacco smoke exposure. Pulm Pharmacol Ther 23(5):376–383
Theron AJ et al (2013) Can the anti-inflammatory activities of beta2-agonists be harnessed in the clinical setting? Drug Des Devel Ther 7:1387–1398
Torrisi SE et al (2018) Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes. Multidiscip Respir Med 13:43
Trapani A et al (2014) Nanocarriers for respiratory diseases treatment: recent advances and current challenges. Curr Top Med Chem 14(9):1133–1147
Travis WD, Travis LB, Devesa SS (1995) Lung cancer. Cancer 75(1 Suppl):191–202
Travis WD et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10(9):1243–1260
Troeger C et al (2018) Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 18(11):1191–1210
van der Eerden BC, Karperien M, Wit JM (2003) Systemic and local regulation of the growth plate. Endocr Rev 24(6):782–801
van Doorn HR, Yu H (2013) Viral respiratory infections. Hunter’s Trop Med Emerg Infect Dis:269–274. https://doi.org/10.1016/B978-1-4160-4390-4.00029-1. Epub 2012 Nov 28
van Gool K et al (2013) Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health 16(2):345–355
Viegi G et al (2020) Global Burden of Chronic Respiratory Diseases. J Aerosol Med Pulm Drug Deliv 33(4):171–177
von Mutius E (2009) Gene-environment interactions in asthma. J Allergy Clin Immunol 123(1):3–11. quiz 12-3
Walker CLF et al (2013) Global burden of childhood pneumonia and diarrhoea. Lancet 381(9875):1405–1416
Wang X et al (2020) Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob Health 8(4):e497–e510
WHO (2020) Asthma: global prevalence. [cited 2020 20th July]. https://www.who.int/news-room/q-a-detail/asthma
Wisnivesky J, De-Torres JP (2019) The global burden of pulmonary diseases: most prevalent problems and opportunities for improvement. Ann Glob Health 85(1):1
Wong AW, Ryerson CJ, Guler SA (2020) Progression of fibrosing interstitial lung disease. Respir Res 21(1):32
Woodruff PG et al (2016) Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 374(19):1811–1821
World Bank (2020)
World Health Organization (2019) Global Tuberculosis Report
World Health Organization, G., Switzerland (2018a). Global tuberculosis report 2018. https://www.who.int/tb/publications/global_report/en/
World Health Organization, G., Switzerland (2018b). https://www.who.int/news-room/fact-sheets/detail/cancer
Worlitzsch D et al (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109(3):317–325
Xie M et al (2020) Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017. Respir Res 21(1):49
Zhang X, Moilanen E, Kankaanranta H (2001) Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol 431(3):365–371
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Sunkara, K. et al. (2022). An Introduction to Respiratory Diseases and an Emerging Need for Efficient Drug Delivery Systems. In: Chellappan, D.K., Pabreja, K., Faiyazuddin, M. (eds) Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases . Springer, Singapore. https://doi.org/10.1007/978-981-16-4392-7_1
Download citation
DOI: https://doi.org/10.1007/978-981-16-4392-7_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-4391-0
Online ISBN: 978-981-16-4392-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)